



DPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Kendall M. Mohler, Docket No.: 2959-B  
Dauphine S. Barone, Jacques J. Peschon,  
Mary K. Kennedy and John D Pluenneke

Serial No.: 10/648,136

Examiner: Maher M. Haddad

Filed: August 26, 2003

Art Unit: 1644

For: METHODS FOR TREATING AUTOIMMUNE AND CHRONIC  
INFLAMMATORY CONDITIONS USING ANTAGONISTS OF CD30  
AND CD30L

**RESPONSE TO RESTRICTION REQUIREMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This paper is filed in response to the Office Action dated September 20, 2005, in which the Examiner required restriction of the elected invention to the subject matter of one of the following (6) groups of claims:

- Group I. Claims 3-21, drawn to a method of treating an autoimmune or chronic inflammatory condition in a patient, wherein agent is an antibody that is specific for CD30L, and the second agent is an antagonist of TNF $\alpha$ , classified in Class 424, subclass 130.1.
- Group II. Claims 3-6 and 12-23, drawn to a method of treating an autoimmune or chronic inflammatory condition in a patient, wherein agent is an antibody that is specific for CD30L, and the second agent is an antagonist of IL-1 $\alpha$ , classified in Class 424, subclass 130.1.
- Group III. Claims 3-6 and 12-23, drawn to a method of treating an autoimmune or chronic inflammatory condition in a patient, wherein agent is an antibody that is specific for CD30L, and the second agent is an antagonist of IL-1 $\beta$ , classified in Class 424, subclass 130.1.
- Group IV. Claims 3-6 and 12-23, drawn to a method of treating an autoimmune or chronic inflammatory condition in a patient, wherein agent is an antibody that is specific for CD30L, and the second agent is an antagonist of IL-4, as it reads on an *antibody specific for IL-4*; classified in Class 424, subclass 130.1.